Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

Unicancer

Status and phase

Terminated

Phase 2

Conditions

Colorectal Cancer

Treatments

Radiation: radiation therapy

Drug: leucovorin calcium

Drug: oxaliplatin

Drug: capecitabine

Drug: fluorouracil

Procedure: conventional surgery

Procedure: adjuvant therapy

Biological: cetuximab

Procedure: neoadjuvant therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT00541112

EU-20759

2006-003336-30 (EudraCT Number)

CDR0000565937

FRE-FNCLCC-ACCORD-14/0604 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy together with combination chemotherapy and cetuximab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy and cetuximab after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II clinical trial is studying how well giving radiation therapy together with chemotherapy and cetuximab followed by surgery, chemotherapy, and cetuximab works in treating patients with locally advanced or metastatic rectal cancer that can be removed by surgery.

Full description

OBJECTIVES:

Primary

Determine the complete remission rate at 6 months after neoadjuvant radiotherapy, capecitabine, and oxaliplatin (XELOX), and cetuximab followed by surgery, adjuvant FOLFOX 4, and cetuximab in patients with synchronous locally advanced or metastatic cancer of the rectum with resectable metastases (T3-4 Nx or T2 N+ M1).

Secondary

Determine progression-free survival.
Determine overall survival.
Assess toxicities.
Evaluate objective response in patients with measurable metastases.
Determine the rate of local recurrence.
Evaluate the downstaging and downsizing of patients with operable disease.
Evaluate surgical complications in patients with operable disease.
Evaluate biological markers predictive of response to cetuximab.

OUTLINE: This is a multicenter study.

Neoadjuvant therapy: Patients undergo radiotherapy for 5 weeks and receive concurrent oral capecitabine twice daily on days 1-5 of each week and oxaliplatin IV over 2 hours on day 1 of each week (XELOX). Patients also receive cetuximab IV on day 1 of the first week and on days 1-7 of weeks 2-5.
Surgery: At 6 weeks after completing chemoradiotherapy, patients with resectable disease undergo surgery comprising total mesorectal excision. Patients with progressive disease, nonresectable tumor, or who require R2 surgery are removed from the study.
Adjuvant therapy: Patients who undergo surgery, with or without removal of metastases, receive FOLFOX 4, comprising oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours, and leucovorin calcium IV on day 1, and cetuximab IV. Treatment repeats every 2 weeks for up to 6 courses (approximately 3 months). Patients who have not undergone prior surgical resection of metastases may have surgery to remove metastases after completing this second regimen of chemotherapy.

After completion of study therapy, patients are followed periodically for up to 5 years.

Enrollment

19 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the rectum
- Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease
  - Metastases must be resectable
- Primary tumor examined by endorectal echography and MRI
Measurable disease by thoraco-abdomino-pelvic scanner
Disease considered susceptible to treatment with radiotherapy and chemotherapy
No diffuse metastases considered nonresectable
No acute occlusion not caused by colostomy

PATIENT CHARACTERISTICS:

Inclusion criteria:

ECOG performance status 0-2
WBC ≥ 4,000/mm^3
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 10 g/dL
Creatinine ≤ 130 µmol/L
Transaminases ≤ 5 times upper limit of normal (ULN)
Total bilirubin ≤ 1.5 times ULN
Alkaline phosphatase ≤ 2.5 times ULN
Not pregnant or nursing
Negative pregnancy test
Fertile patients of must use effective contraception

Exclusion criteria:

Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or radiotherapy
Impossible to perform translational analyses
Uncontrolled severe illness
Severe renal or hepatic insufficiency
Cardiac insufficiency or symptomatic coronary disease
Sensitive peripheral neuropathy
Uncontrolled diabetes
Other malignancy within the past 10 years except previously treated basal cell skin cancer or carcinoma in situ of the cervix
Impossible to participate in study due to geographic, social, or psychiatric reasons
Patients who are under supervision or incarcerated

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No prior anticancer chemotherapy or radiotherapy for this cancer
No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids, or allopurinol
No concurrent participation in another therapeutic study or receiving another experimental drug